Skip to main content

Table 3 Frequencies of benzodiazepine use in participants

From: Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial

 

Baselinea

Week 1

Week 2

Week 6

Week 12

Week 24

Mirtazapine

n = 20

n = 17

n = 15

n = 14

n = 9

n = 8

Non-use, n (%)

 

8 (47.1)

7 (46.7)

11 (78.6)

8 (88.9)

7 (87.5)

1–6 days per week, n (%)

 

5 (29.4)

4 (26.7)

1 (7.1)

0 (0.0)

0 (0.0)

Every day, n (%)

 

4 (23.5)

4 (26.7)

2 (14.3)

1 (11.1)

1 (12.5)

SSRIs

n = 45

n = 43

n = 42

n = 33

n = 28

n = 22

Non-use, n (%)

 

12 (27.9)

14 (33.3)

6 (18.2)

4 (14.3)

4 (18.2)

1–6 days per week, n (%)

 

15 (34.9)

8 (19.0)

12 (36.4)

9 (32.1)

4 (18.2)

Every day, n (%)

 

16 (37.2)

20 (47.6)

15 (45.5)

15 (53.6)

14 (63.6)

Sertraline

n = 28

n = 26

n = 26

n = 22

n = 19

n = 15

Non-use, n (%)

 

7 (26.9)

9 (34.6)

5 (22.7)

3 (15.8)

3 (20.0)

1–6 days per week, n (%)

 

8 (30.8)

4 (15.4)

7 (31.8)

5 (26.3)

2 (13.3)

Every day, n (%)

 

11 (42.3)

13 (50.0)

10 (45.5)

11 (57.9)

10 (66.7)

Paroxetine

n = 17

n = 17

n = 16

n = 11

n = 9

n = 7

Non-use, n (%)

 

5 (29.4)

5 (31.3)

1 (9.1)

1 (11.1)

1 (14.3)

1–6 day per week, n (%)

 

7 (41.2)

4 (25.0)

5 (45.5)

4 (44.4)

2 (28.6)

Every day, n (%)

 

5 (29.4)

7 (43.8)

5 (45.5)

4 (44.4)

4 (57.1)

  1. SSRI selective serotonin reuptake inhibitor
  2. aPatients prescribed benzodiazepines at baseline (day 1) were only counted in numbers in this table